Dextrothyroxine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name = (2''R'')-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid | | IUPAC_name = (2''R'')-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid | ||
| image = | | image = Dextrothyroxine.png | ||
| alt = | | alt = | ||
| caption = | | caption = | ||
| Line 53: | Line 53: | ||
==Overview== | ==Overview== | ||
'''Dextrothyroxine''' (trade name '''Choloxin''') saw research as an | '''Dextrothyroxine''' (trade name '''Choloxin''') saw research as an cholesterol-lowering drug<ref>{{cite pmid|6475988}}</ref><ref>{{cite pmid|9440092}}</ref> but was pulled due to cardiac side-effects. It also increases [[hepatic lipase]] which in turn improves utilization of triglycerides, improving [[apolipoprotein E]] cholesterol particles.{{fact|date=March 2012}} | ||
==See Also== | ==See Also== | ||
Revision as of 17:22, 27 July 2014
 | |
| Clinical data | |
|---|---|
| Trade names | Choloxin |
| Synonyms | D-3,5,3',5'-tetraiodothyronine |
| AHFS/Drugs.com | Multum Consumer Information |
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H11I4NO4 |
| Molar mass | 776.87 g/mol |
| 3D model (JSmol) | |
| |
| |
|
WikiDoc Resources for Dextrothyroxine |
|
Articles |
|---|
|
Most recent articles on Dextrothyroxine Most cited articles on Dextrothyroxine |
|
Media |
|
Powerpoint slides on Dextrothyroxine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dextrothyroxine at Clinical Trials.gov Trial results on Dextrothyroxine Clinical Trials on Dextrothyroxine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dextrothyroxine NICE Guidance on Dextrothyroxine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dextrothyroxine Discussion groups on Dextrothyroxine Patient Handouts on Dextrothyroxine Directions to Hospitals Treating Dextrothyroxine Risk calculators and risk factors for Dextrothyroxine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dextrothyroxine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dextrothyroxine (trade name Choloxin) saw research as an cholesterol-lowering drug[1][2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.[citation needed]
See Also
References
- ↑ PMID 6475988 (PMID 6475988)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 9440092 (PMID 9440092)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
- Pages with script errors
- Pages with incomplete PMID references
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without KEGG source
- Articles containing unverified chemical infoboxes
- All articles with unsourced statements
- Articles with unsourced statements from March 2012
- Articles with invalid date parameter in template
- Drug
- Cardiovascular Drugs
- Hypolipidemic agents